A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...

The slew of news from the JP Morgan Healthcare conference that started this morning started with a trio of takeover deals from Johnson & Johnson, Novartis, and MSD. J&J’s $2 billion play for ...

President Trump on Monday night announced tariffs of 10% on softwood timber and lumber alongside a 25% tariff on "certain upholstered wooden products" due to take effect on Oct. 14, according to the ...